- Home
- XNET vs MYGN Comparison
XNET vs MYGN Comparison
Compare XNET & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XNET
- MYGN
- Stock Information
- Founded
- XNET 2003
- MYGN 1991
- Country
- XNET China
- MYGN United States
- Employees
- XNET N/A
- MYGN N/A
- Industry
- XNET Computer Software: Prepackaged Software
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- XNET Technology
- MYGN Health Care
- Exchange
- XNET Nasdaq
- MYGN Nasdaq
- Market Cap
- XNET 373.0M
- MYGN 423.1M
- IPO Year
- XNET 2014
- MYGN 1995
- Fundamental
- Price
- XNET $4.48
- MYGN $6.32
- Analyst Decision
- XNET
- MYGN Hold
- Analyst Count
- XNET 0
- MYGN 15
- Target Price
- XNET N/A
- MYGN $15.14
- AVG Volume (30 Days)
- XNET 387.2K
- MYGN 2.3M
- Earning Date
- XNET 08-14-2025
- MYGN 08-05-2025
- Dividend Yield
- XNET N/A
- MYGN N/A
- EPS Growth
- XNET N/A
- MYGN N/A
- EPS
- XNET N/A
- MYGN N/A
- Revenue
- XNET $331,614,000.00
- MYGN $832,900,000.00
- Revenue This Year
- XNET N/A
- MYGN N/A
- Revenue Next Year
- XNET N/A
- MYGN $6.64
- P/E Ratio
- XNET N/A
- MYGN N/A
- Revenue Growth
- XNET N/A
- MYGN 3.83
- 52 Week Low
- XNET $1.51
- MYGN $3.76
- 52 Week High
- XNET $7.19
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- XNET 44.70
- MYGN 70.39
- Support Level
- XNET $4.14
- MYGN $3.76
- Resistance Level
- XNET $4.84
- MYGN $4.09
- Average True Range (ATR)
- XNET 0.26
- MYGN 0.30
- MACD
- XNET -0.01
- MYGN 0.23
- Stochastic Oscillator
- XNET 28.81
- MYGN 96.97
About XNET Xunlei Limited
Xunlei Ltd is a cloud-based acceleration technology company in China. The company operates a powerful internet platform in China based on cloud computing to provide users with quick and easy access to digital media content through its products and services, Xunlei Accelerator, and cloud acceleration subscription services. It is increasingly extending into mobile devices in part through potentially pre-installed acceleration products in mobile phones Xunlei has developed various value-added services to meet a fuller spectrum of its users' digital media content access and consumption needs.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.